Navigation Links
Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
Date:11/13/2008

- The cash and cash equivalents available at September 30, 2008 and our ability to control certain costs, including those related to clinical trial programs, preclinical activities, and certain general and administrative expenses has enabled us to meet our anticipated cash expenditures into November 2008. We must immediately raise additional funds in November 2008 in order to continue operations.

Alseres Pharmaceuticals Upcoming Milestones

-- Enrollment in the first part of the POET-2 Phase III clinical trial for our Altropane molecular imaging agent is expected to be complete in early 2009. We are currently identifying appropriate sites and investigators for the Phase III, POET-2 registration trials which are planned to be initiated in mid-2009.

-- Twelve month interim data for the Phase I/IIa clinical trial of Cethrin will be presented at the Society for Neuroscience Meeting, November 15-19, 2008, in Washington, DC by Dr. Michael Fehlings, principal Investigator of the Cethrin Phase I/IIa trial.

-- We are pursuing development and commercialization partnerships for our molecular imaging and regenerative therapy assets. We expect to continue confidential discussions with franchise leaders interested in our molecular imaging and regenerative therapeutic pipelines. We expect to advance discussions toward partnerships and scientific collaborations over the remainder of the year.

Conference Call Access Information

The company will host a conference call to discuss results on November 14, 2008, at 9:00 a.m. Eastern Time. To access the conference call, please dial 877-718-5095 for domestic and 719-325-4818 for international calls. The code for this conference call is 3501954. Please dial in 5 to 10 minutes prior to the scheduled start time. A replay of the call will be posted on the Investor Relations section of our website, http://www.alseres.com, within 48 hours following the co
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Alseres Pharmaceuticals, Inc. Raises $5 Million
2. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
3. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
4. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
5. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
6. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
7. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
8. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
9. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
10. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
11. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... At the request of the AMA, the Federal ... the public comment period (Docket No. FAA-2014-0396) for FAA’s ... by Congress as part of the FAA Modernization and ... new deadline for comments as September 23, 2014. , ... in the Federal Register on July 25, 2014, the ...
(Date:7/24/2014)... Tenn., July 24, 2014 -- A novel combination of ... Department of Energy,s Oak Ridge National Laboratory an unprecedented ... its unusual physical and electrochemical properties. , The ... oxygen affects the surface of a perovskite manganite, a ... The new avenue to understand surface behavior could benefit ...
(Date:7/24/2014)... July 24, 2014  Asterias Biotherapeutics, Inc. (OTCBB: ... field of regenerative medicine, announced today that it ... to investors on Tuesday, July 29, 2014, at ... will include an overview of Asterias, business strategy ... visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes ...
(Date:7/24/2014)... leader Yung-Eun Sung has announced that they have ... graphenes which can be applied as high performance ... Sung is both a group leader at the ... Science* (IBS) and a professor at the Seoul ... with regards to the development of relative simplicity, ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2ORNL study reveals new characteristics of complex oxide surfaces 2Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... , THOROLD, ON , ... innovative privately held Canadian biotechnology company focusing primarily on ... purification, today announced the launch of 10 new kits ... from blood, plasma and serum, including circulating nucleic acids. ...
... , Collaboration will further evaluate novel stem cell-derived ... genes relevant to disease progression , CAMBRIDGE, Mass. ... California Stem Cell, Inc. (CSC) and ALS Therapy Development ... expansion of their collaboration aimed at advancing a potential stem ...
... SANTA ROSA, Calif. , Feb. 2 Just in ... introduces the newest in their scientifically formulated product line: CIRCUTOL™ Cardiovascular ... in 1995 by integrative medicine pioneer, Dr. Isaac Eliaz ... being at the forefront of the latest developments in natural alternative health ...
Cached Biology Technology:Norgen Biotek Launches 10 New Kits for the Isolation of High-Quality Circulating Nucleic Acids from Blood, Plasma and Serum 2California Stem Cell and ALS Therapy Development Institute Extend Their Collaboration to Advance Potential Stem Cell Assisted Therapy for ALS 2California Stem Cell and ALS Therapy Development Institute Extend Their Collaboration to Advance Potential Stem Cell Assisted Therapy for ALS 3California Stem Cell and ALS Therapy Development Institute Extend Their Collaboration to Advance Potential Stem Cell Assisted Therapy for ALS 4Just in Time for Heart Health Month... TRIPLE Cardiovascular Health Support From EcoNugenics 2Just in Time for Heart Health Month... TRIPLE Cardiovascular Health Support From EcoNugenics 3
(Date:7/24/2014)... Scientists at The New York Stem Cell ... to creating a viable cell replacement therapy for ... , For the first time, NYSCF scientists generated ... samples of patients with primary progressive multiple sclerosis ... induce these stem cells into becoming oligodendrocytes, the ...
(Date:7/24/2014)... 24, 2014) Scientists at The New York ... step closer to creating a viable cell replacement ... cells. , For the first time, NYSCF ... from skin samples of patients with primary progressive ... protocol to induce these stem cells into becoming ...
(Date:7/24/2014)... identified two factors that characterize sustainable university and ... highly qualified physics teachers. Specifically, one or more ... education in combination with institutional motivation and commitment ... Technology, Engineering and Math (STEM) teacher shortages are ... the way for institutions seeking to increase the ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Creating sustainable STEM teacher preparation programs 2
... 25, 2010 - A first-of-its-kind study of a Caspian ... current harvest rates are four to five times higher ... results, which will be published in an upcoming issue ... conservation strategies for beluga sturgeon should focus on reducing ...
... A study involving the world,s deadliest substance has yielded a ... to more efficient strategies against toxins that may be used ... stings, and even some important chronic diseases. A ... agents that seek out Botulinum toxin molecules and bind to ...
... as they evolved over hundreds of generations to infect bacteria. ... the viruses evolved at a quicker rate and generated greater ... adapt to the viral infection. The study shows, for ... Valen was correct in his ,Red Queen Hypothesis,. The ...
Cached Biology News:New research shows fishery management practices for beluga sturgeon must change 2New research shows fishery management practices for beluga sturgeon must change 3Novel antitoxin strategy developed using 'tagged binding agents' 2Novel antitoxin strategy developed using 'tagged binding agents' 3Scientists reveal driving force behind evolution 2
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
... Proteolytic degradation is critical to the ... and regulatory proteins as important and ... metabolism, heat shock and stress response, ... receptors and ion channels, cell cycle ...
... Optics LIBS2000+ Spectrometers (sold separately) in the ... Chamber to offer numerous configuration options and ... include a high-power 1064 nm Nd:YAG laser, ... sample positioning, laser spot diameter control from ...
... Picking,A modified digital scanner serves as the ... the five standard rack positions on the ... micro well plates on the remaining two ... single spots by mouse-click on the scanned ...
Biology Products: